The Reduced Expression Level of MST1 gene in Patients with Prostate Cancer

Prostate cancer (PC) is the second most common malignancy in men, accounting for 12.5% of total number of cancers. The development of molecular studies (such as transcriptomics analysis) helps to characterization of Cancer, development of new targets for therapy, and introduction of the novel prognostic and diagnostic biomarkers. Recent studies have confirmed Mammalian Sterile 20-Like kinase (MST1) as a tumor suppressor gene. In this study we focus on MST1 expression level in WBC of PC patients, due to inheritance pattern of PC. Material and This case-control study was conducted in two groups (20 patients with PC and 20 healthy individuals). After RNA extraction and cDNA synthesis, quantitative Real-Time PCR was done in order to determine the MST1 expression level. GAPDH was considered as internal control gene. Statistical analysis was performed by “Rotor-Gene Q series software 2.3.1” and “Rest 2.0.13 software”. the study on 20 PC patients aged 50 to 70 years old and 20 healthy individuals shown that MST1 expression level in the WBC samples of PC patients have been reduced ≈62% compared to normal individuals. Introducing of reduced expression level of MST1 as a prostate cancer biomarker needs to more complementary studies. But in this study, biomarker validation potential of MST1 has been approved.